CTSO

Cytosorbents Corp

Add to Watchlist

Advanced Chart

0.710

-0.035(-4.698%)1D

Line

Candle

YTD

High

0.749

Open

0.7399

VWAP

0.73

Vol

80.80K

Mkt Cap

44.88M

Low

0.7101

Amount

59.16K

EV/EBITDA(TTM)

Total Shares

54.31M

50.93M

EV/OCF(TTM)

P/S(TTM)

1.22

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

10.60M

+21.46%

-0.050

+150%

10.68M

+5.71%

-0.050

-64.29%

10.02M

+6.69%

-0.047

+16.68%

Estimates Revision

The market is revising Downward the revenue expectations for Cytosorbents Corporation (CTSO) for FY2025, with the revenue forecasts being adjusted by -1.9% over the past three months. During the same period, the stock price has changed by -21.24%.

Revenue Estimates for FY2025

Revise Downward

-1.9%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.25%

In Past 3 Month

Stock Price

Go Down

-21.24%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CTSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSO is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 0.710

Low

1.00

Averages

1.00

High

1.00

Current: 0.710

Low

1.00

Averages

1.00

High

1.00

HC Wainwright & Co.

Sean Lee

Hold

Reiterates

2025-04-03

Reason

HC Wainwright & Co.

Sean Lee

Price Target

2025-04-03

Reiterates

Hold

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-04-01

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-04-01

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-01-13

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-01-13

Maintains

Strong Buy

Reason

D. Boral Capital says CytoSorbents reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents' strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-01-03

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-01-03

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2024-11-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2024-11-12

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Sean Lee

Hold

Reiterates

2024-11-11

Reason

HC Wainwright & Co.

Sean Lee

Price Target

2024-11-11

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cytosorbents Corp (CTSO.O) is -3.79, compared to its 5-year average forward P/E of -11.64. For a more detailed relative valuation and DCF analysis to assess Cytosorbents Corp 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.64

Current PE

-3.79

Overvalued PE

3.93

Undervalued PE

-27.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-132.85

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

281.43

Undervalued EV/EBITDA

-547.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

3.35

Current PS

0.74

Overvalued PS

5.88

Undervalued PS

0.81

Financials

Annual

Quarterly

FY2025Q2

YoY :

+8.76%

9.62M

Total Revenue

FY2025Q2

YoY :

+1.26%

-3.62M

Operating Profit

FY2025Q2

YoY :

-145.34%

1.95M

Net Income after Tax

FY2025Q2

YoY :

-137.50%

0.03

EPS - Diluted

FY2025Q2

YoY :

-66.58%

-1.64M

Free Cash Flow

FY2025Q2

YoY :

-3.67%

70.85

Gross Profit Margin - %

FY2025Q2

YoY :

-60.51%

-28.75

FCF Margin - %

FY2025Q2

YoY :

-141.70%

20.25

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

47.3K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

168.4K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

47.3K

USD

Months

CTSO News & Events

Events Timeline

2025-09-16 (ET)

2025-09-16

07:09:03

CytoSorbents announces regulatory progress for DrugSorb-ATR

2025-08-20 (ET)

2025-08-20

07:09:25

CytoSorbents gives update on FDA appeal for DrugSorb-ATR

2025-08-07 (ET)

2025-08-07

16:04:46

CytoSorbents reports Q 2 adjusted EPS (5c) vs. (5c) last year

News

5.0

10-28PRnewswire

In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

1.0

09-29PRnewswire

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

9.0

09-16NASDAQ.COM

CytoSorbents Provides Regulatory Update on DrugSorb-ATR and Intends to Submit New De Novo Application